Stock Events

Stock Events

Pharvaris NV 

€24.6
4
-€0.8-3.15% Today

Statistics

Day High
24.8
Day Low
24.4
52W High
25.4
52W Low
10.3
Volume
-
Avg. Volume
-
Mkt Cap
1.6B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14AprExpected
Q1 2024
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Next
-0.98
-0.84
-0.7
-0.56
Expected EPS
-0.70530852363
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-268.44MNet Income

Analyst Ratings

$34.40Average Price Target
The highest estimate is 45.53.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
83%
Hold
17%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 9EN.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical Inc. develops and commercializes innovative therapies for patients with serious and life-threatening rare diseases and medical conditions, including genetic disorders, which is a similar focus area to Pharvaris' work on hereditary angioedema.
Takeda Pharmaceutical
TAK
Mkt Cap42.62B
Takeda Pharmaceutical Company Limited operates in various therapeutic areas, including rare diseases, which aligns with Pharvaris' focus on providing treatments for rare conditions like hereditary angioedema.
Carlisle Companies
CSL
Mkt Cap13.58B
CSL Behring is a global biotherapies leader which develops and delivers innovative therapies for people with rare and serious diseases, competing directly in the space of treatments for conditions like those Pharvaris targets.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals, Inc. is a leader in RNAi therapeutics for the treatment of rare genetic diseases, which competes with Pharvaris' approach to targeting genetic disorders.
Biogen
BIIB
Mkt Cap22.63B
Biogen Inc. focuses on developing therapies for neurological and neurodegenerative diseases, along with rare diseases, positioning it as a competitor in the rare disease sector.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics, Inc. is focused on the discovery and development of RNA-based therapeutics for the treatment of rare diseases, directly competing with Pharvaris' focus areas.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. is a global biotechnology company that develops and produces innovative human therapeutics, including treatments for rare diseases, making it a competitor in the rare disease therapeutic market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its development of treatments for serious medical conditions, including rare diseases, which places it in direct competition with Pharvaris in the rare disease market.

About

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist for the treatment of attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), as well as in Phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Show more...
CEO
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
Employees
114
Country
NL
ISIN
NL00150005Y4
WKN
000A2QNWS

Listings

XNAS
US
PHVS
F
DE
9EN.F
BOATS
BOATS
PHVS.BOATS

0 Comments

Share your thoughts

FAQ

What is Pharvaris NV stock price today?▼
The current price of 9EN.F is €24.6 EUR — it has decreased by -3.15% in the past 24 hours. Watch Pharvaris NV stock price performance more closely on the chart.
What is Pharvaris NV stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Pharvaris NV stocks are traded under the ticker 9EN.F.
Is Pharvaris NV stock price growing?▼
9EN.F stock has risen by +4.24% compared to the previous week, the month change is a +3.36% rise, over the last year Pharvaris NV has showed a +83.58% increase.
What is Pharvaris NV market cap?▼
Today Pharvaris NV has the market capitalization of 1.6B
When is the next Pharvaris NV earnings date?▼
Pharvaris NV is going to release the next earnings report on April 14, 2026.
What were Pharvaris NV earnings last quarter?▼
9EN.F earnings for the last quarter are -0.61 EUR per share, whereas the estimation was -0.68 EUR resulting in a +10.04% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pharvaris NV revenue for the last year?▼
Pharvaris NV revenue for the last year amounts to 0 EUR.
What is Pharvaris NV net income for the last year?▼
9EN.F net income for the last year is -268.44M EUR.
How many employees does Pharvaris NV have?▼
As of April 02, 2026, the company has 114 employees.
In which sector is Pharvaris NV located?▼
Pharvaris NV operates in the Health Care sector.
When did Pharvaris NV complete a stock split?▼
Pharvaris NV has not had any recent stock splits.
Where is Pharvaris NV headquartered?▼
Pharvaris NV is headquartered in Zug, NL.